Processa Pharmaceuticals (PCSA) Gross Margin (2012 - 2016)
Processa Pharmaceuticals' (PCSA) quarterly Gross Margin came in at 100.0% in Q1 2016, up 6095.0% YoY from 1.61% in Q2 2015, and up 142.9% on a QoQ basis from 233.1% in Q4 2015.
Processa Pharmaceuticals (PCSA) Gross Margin (2012 - 2016) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 5 years of Gross Margin data on file, last reported at 100.0% in Q1 2016.
- Quarterly Gross Margin rose 6095.0% year-over-year to 100.0% in Q1 2016, while the trailing twelve-month figure through Dec 2016 was 100.0% (up 10389.0% YoY) and the FY2016 annual result came in at 100.0%, up 11098.0% from the prior year.
- Gross Margin improved to 100.0% in Q1 2016, from 233.1% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 100.0% in Q1 2016 to a low of 283.15% in Q4 2014.
- A 5-year average of 11.37% and a median of 41.79% in 2015 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2014 — Gross Margin slumped 33478 bps — and 2016, when it soared 6095 bps.
- Tracing PCSA's Gross Margin over 5 years: stood at 5.26% in 2012, then soared by 1081 bps to 51.63% in 2013, then slumped by 648 bps to 283.15% in 2014, then rose by 18 bps to 233.1% in 2015, then jumped by 143 bps to 100.0% in 2016.
- The last three Gross Margin figures came in at 100.0% (Q1 2016), 233.1% (Q4 2015), and 88.37% (Q3 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 100.00% |
| Dec 31, 2015 | -233.10% |
| Sep 30, 2015 | 88.37% |
| Jun 30, 2015 | 45.07% |
| Mar 31, 2015 | 39.05% |
| Dec 31, 2014 | -283.15% |
| Sep 30, 2014 | 51.94% |
| Jun 30, 2014 | 55.38% |
| Mar 31, 2014 | 86.86% |
| Dec 31, 2013 | 51.63% |
| Sep 30, 2013 | 36.11% |
| Jun 30, 2013 | 36.75% |
| Mar 31, 2013 | 36.85% |
| Dec 31, 2012 | -5.26% |
| Sep 30, 2012 | 30.87% |
| Jun 30, 2012 | 44.52% |